SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla collaborates with CSIR-IICT

18 Mar 2020 Evaluate

Hyderabad-based CSIR-Indian Institute of Chemical Technology (IICT) has partnered with Cipla to work on development of anti- viral drugs to contain COVID-19. Research on anti-viral drugs has been on throughout the world for long and many companies have developed molecules having anti-viral properties. But due to lack of demand, these molecules were not widely marketed. However, the CSIR-IICT decided to work on three such molecules -- remdesivir, favipiravir and baloxavir.

Cipla urged the IICT director S Chandrasekhar to start work on these molecules on an immediate basis. Cipla would upscale the process on the basis of know-how given by CSIR-IICT.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1365.25 31.70 (2.38%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×